On October 8, 2026, a clinical trial update was recorded for the study titled "Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer." The trial, registered under identifier NCT05346848, is listed as Phase 2. Its current status is recruiting, meaning the trial is actively enrolling participants as of this update. The study examines darolutamide given alongside radiation therapy in patients with intermediate unfavorable risk prostate cancer. No results or outcome data have been reported as part of this update. The trial record does not indicate findings on efficacy or safety at this stage. Gonadorelin is noted in connection with this trial record and is an approved compound. No additional details about dosing, endpoints, or results are included in this update. Readers seeking more background on gonadorelin can consult the compound overview for further context.
Gonadorelin-Linked Phase II Darolutamide Trial Update, Oct 2026
See the full gonadorelin overview
Source: https://clinicaltrials.gov/study/NCT05346848